stockrow
Saturday 7 November 2026
Export IGC’s income statement to Excel — free account
IGC Pharma, Inc.
IGC Pharma, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $1.3 million, down 5.50% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- 0.00%
- Free cash flow
- −45.3%
- Total debt
- +558.3%
Quarter to September 2026, against a year earlier
0.19
0.00
0.00%
Follow IGC
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 21.89 | 24.60 | 26.85 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (20.87) | (20.07) | (20.86) | |
P/B ratio |
— | 4.17 | 4.42 | 4.55 | |
Price to Tangible BV |
— | 29.92 | 43.34 | 38.85 | |
EV/Sales |
— | 22.47 | 25.27 | 27.26 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (5.55) | (5.21) | (5.61) | |
EV/FCF |
— | (5.56) | (4.89) | (5.27) | |
Quick Ratio |
0.44 | 0.09 | 0.13 | 0.16 | |
Current Ratio |
0.83 | 0.40 | 0.39 | 0.42 | |
Net Debt/EBITDA |
0.00 | (0.28) | (0.27) | 0.00 | |
Debt/Assets |
3.20% | 9.98% | 11.39% | 8.93% | |
Debt/Equity |
0.04 | 0.15 | 0.18 | 0.13 | |
Asset Turnover |
0.00 | 0.13 | 0.13 | 0.11 | |
Operating CF/Net income |
— | 0.51 | 0.46 | 0.69 | |
Capex/Depreciation |
— | (0.02) | (7.55) | 0.00 | |
Research and Development Expense of Revenue |
— | 401.26% | 524.53% | 308.84% | |
Selling, General and Administrative Expense of Revenue |
— | 391.48% | 544.15% | 298.48% | |
Intangible Assets out of Total Assets |
0.53 | 0.57 | 0.58 | 0.59 | |
Share Based Compensation of Revenue |
— | 318.30% | 281.89% | 118.90% | |
Graham Net Nets |
— | (0.08) | (0.08) | (0.06) | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (28.85%) | (33.33%) | (33.33%) | |
Free Cash Flow Yield |
— | (18.47%) | (20.99%) | (19.27%) | |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
— | (0.01) | (0.01) | (0.01) | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | (0.01) | (0.02) | (0.01) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.06 | 0.06 | 0.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.06 | 0.06 | 0.06 | |
Free Cash Flow |
— | (1.22) | (1.77) | (1.42) | |
Working Capital |
(0.37) | (1.73) | (1.95) | (1.79) | |
Capital Expenditures |
— | 0.00 | (0.42) | — | |
Net Current Asset Value |
(0.50) | (1.92) | (2.10) | (1.92) | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 1.60 | 0.00 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.03 | 0.04 | 0.07 | 0.05 | |
Average Payables |
0.92 | 1.07 | 1.28 | 1.14 | |
Average Inventory |
1.04 | 1.00 | 0.99 | 0.65 | |
Average Assets |
9.40 | 8.97 | 8.72 | 9.74 | |
Average Common Equity |
6.84 | 6.23 | 6.11 | 7.30 |
Columns are period end dates · fundamentals updated 6 Nov 2026